Search

Your search keyword '"Campone, Mario"' showing total 7 results
Start Over Author "Campone, Mario" Publication Year Range Last 50 years Journal new england journal of medicine
7 results on '"Campone, Mario"'

1. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Author

Hortobagyi, Gabriel N., primary, Stemmer, Salomon M., additional, Burris, Howard A., additional, Yap, Yoon-Sim, additional, Sonke, Gabe S., additional, Hart, Lowell, additional, Campone, Mario, additional, Petrakova, Katarina, additional, Winer, Eric P., additional, Janni, Wolfgang, additional, Conte, Pierfranco, additional, Cameron, David A., additional, André, Fabrice, additional, Arteaga, Carlos L., additional, Zarate, Juan P., additional, Chakravartty, Arunava, additional, Taran, Tetiana, additional, Le Gac, Fabienne, additional, Serra, Paolo, additional, and O’Shaughnessy, Joyce, additional

Published
2022
Full Text
View/download PDF

2. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Author

André, Fabrice, primary, Ciruelos, Eva, additional, Rubovszky, Gabor, additional, Campone, Mario, additional, Loibl, Sibylle, additional, Rugo, Hope S., additional, Iwata, Hiroji, additional, Conte, Pierfranco, additional, Mayer, Ingrid A., additional, Kaufman, Bella, additional, Yamashita, Toshinari, additional, Lu, Yen-Shen, additional, Inoue, Kenichi, additional, Takahashi, Masato, additional, Pápai, Zsuzsanna, additional, Longin, Anne-Sophie, additional, Mills, David, additional, Wilke, Celine, additional, Hirawat, Samit, additional, and Juric, Dejan, additional

Published
2019
Full Text
View/download PDF

3. Lomustine and Bevacizumab in Progressive Glioblastoma

Author

Wick, Wolfgang, primary, Gorlia, Thierry, additional, Bendszus, Martin, additional, Taphoorn, Martin, additional, Sahm, Felix, additional, Harting, Inga, additional, Brandes, Alba A., additional, Taal, Walter, additional, Domont, Julien, additional, Idbaih, Ahmed, additional, Campone, Mario, additional, Clement, Paul M., additional, Stupp, Roger, additional, Fabbro, Michel, additional, Le Rhun, Emilie, additional, Dubois, Francois, additional, Weller, Michael, additional, von Deimling, Andreas, additional, Golfinopoulos, Vassilis, additional, Bromberg, Jacoline C., additional, Platten, Michael, additional, Klein, Martin, additional, and van den Bent, Martin J., additional

Published
2017
Full Text
View/download PDF

4. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Author

Hortobagyi, Gabriel N., primary, Stemmer, Salomon M., additional, Burris, Howard A., additional, Yap, Yoon-Sim, additional, Sonke, Gabe S., additional, Paluch-Shimon, Shani, additional, Campone, Mario, additional, Blackwell, Kimberly L., additional, André, Fabrice, additional, Winer, Eric P., additional, Janni, Wolfgang, additional, Verma, Sunil, additional, Conte, Pierfranco, additional, Arteaga, Carlos L., additional, Cameron, David A., additional, Petrakova, Katarina, additional, Hart, Lowell L., additional, Villanueva, Cristian, additional, Chan, Arlene, additional, Jakobsen, Erik, additional, Nusch, Arnd, additional, Burdaeva, Olga, additional, Grischke, Eva-Maria, additional, Alba, Emilio, additional, Wist, Erik, additional, Marschner, Norbert, additional, Favret, Anne M., additional, Yardley, Denise, additional, Bachelot, Thomas, additional, Tseng, Ling-Ming, additional, Blau, Sibel, additional, Xuan, Fengjuan, additional, Souami, Farida, additional, Miller, Michelle, additional, Germa, Caroline, additional, Hirawat, Samit, additional, and O’Shaughnessy, Joyce, additional

Published
2016
Full Text
View/download PDF

5. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Author

Swain, Sandra M., primary, Baselga, José, additional, Kim, Sung-Bae, additional, Ro, Jungsil, additional, Semiglazov, Vladimir, additional, Campone, Mario, additional, Ciruelos, Eva, additional, Ferrero, Jean-Marc, additional, Schneeweiss, Andreas, additional, Heeson, Sarah, additional, Clark, Emma, additional, Ross, Graham, additional, Benyunes, Mark C., additional, and Cortés, Javier, additional

Published
2015
Full Text
View/download PDF

6. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Author

Baselga, José, primary, Campone, Mario, additional, Piccart, Martine, additional, Burris, Howard A., additional, Rugo, Hope S., additional, Sahmoud, Tarek, additional, Noguchi, Shinzaburo, additional, Gnant, Michael, additional, Pritchard, Kathleen I., additional, Lebrun, Fabienne, additional, Beck, J. Thaddeus, additional, Ito, Yoshinori, additional, Yardley, Denise, additional, Deleu, Ines, additional, Perez, Alejandra, additional, Bachelot, Thomas, additional, Vittori, Luc, additional, Xu, Zhiying, additional, Mukhopadhyay, Pabak, additional, Lebwohl, David, additional, and Hortobagyi, Gabriel N., additional

Published
2012
Full Text
View/download PDF

7. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer.

Author

Geyer, Charles E., Forster, John, Lindquist, Deborah, Chan, Stephen, Romieu, C. Gilles, Pienkowski, Tadeusz, Jagiello-Gruszfeld, Agnieszka, Crown, John, Chan, Arlene, Kaufman, Bella, Skarlos, Dimosthenis, Campone, Mario, Davidson, Neville, Berger, Mark, Oliva, Cristina, Rubin, Stephen D., Stein, Steven, and Cameron, David

Subjects
*BREAST cancer, *CANCER in women, *CANCER treatment, *CLINICAL medicine, *DRUG efficacy, *MEDICAL research
Abstract

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients. Methods: Women with HER2-positive, locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab were randomly assigned to receive either combination therapy (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter of body-surface area on days 1 through 14 of a 21-day cycle) or monotherapy (capecitabine alone at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle). The primary end point was time to progression, based on an evaluation by independent reviewers under blinded conditions. Results: The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P<0.001), with 49 events in the combination-therapy group and 72 events in the monotherapy group. The median time to progression was 8.4 months in the combination-therapy group as compared with 4.4 months in the monotherapy group. This improvement was achieved without an increase in serious toxic effects or symptomatic cardiac events. Conclusions: Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. (ClinicalTrials.gov number, NCT00078572.) N Engl J Med 2006;355:2733-43. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results